QCG
TVRD

Quadrant Capital Group’s Tvardi Therapeutics TVRD Stock Holding History

Quadrant Capital Group’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-25
Closed -$9.73K – 2800
2022
Q4 		$9.73K Buy
+25
New +$9.49K ﹤0.01% 1961
2022
Q2 		– Sell
-1
Closed – – 2780
2022
Q1 		$0 Hold
1
– – ﹤0.01% 2723
2021
Q4 		$0 Sell
1
-1
-50% -$502 ﹤0.01% 2727
2021
Q3 		$1K Buy
+2
New +$1K ﹤0.01% 2418
2021
Q2 		– Hold
0
– – – 2602
2021
Q1 		– Hold
0
– – – 2475
2020
Q2 		– Hold
0
– – – 2428
2020
Q1 		– Hold
0
– – – 2281

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Quadrant Capital Group's TVRD Position: Q1 2023 in Review

Quadrant Capital Group sold out of Tvardi Therapeutics (TVRD) in Q1 2023, closing a stake of 25 shares — an estimated $9.73K sold.

Quadrant Capital Group first reported a position in TVRD in Q3 2021 and held it in 4 quarters. The position peaked at $9.73K in Q4 2022. 162 funds tracked by Wall St. Rank hold TVRD as of Q1 2023.

  • Quadrant Capital Group reported no remaining Tvardi Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Quadrant Capital Group sold 25 Tvardi Therapeutics shares in Q1 2023, an estimated $9.73K.
  • Quadrant Capital Group first reported a position in Tvardi Therapeutics in Q3 2021 and held it in 4 quarters.
  • Quadrant Capital Group's Tvardi Therapeutics position peaked at $9.73K in Q4 2022.
  • 162 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2023.

Based on Quadrant Capital Group's 13F filing for Q1 2023, filed 11 May 2023.